Results 181 to 190 of about 274,125 (232)

Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women: A 52-week long-term follow-up.

Maturitas
OBJECTIVES To evaluate the long-term efficacy and safety of a single injection session of cross-linked hyaluronic acid for postmenopausal vulvovaginal atrophy. STUDY DESIGN 12-week, randomised, placebo-controlled, single-blind phase followed by 40-week
Hichem Bensmail, Fabienne Marchand Lamiraud, C. Martin, Sofie Pelckmans, Firas Cha'ban, Aliette Siboni Frisch, Gulcan Deniz, Pascale Sabban Serfati, Brigitte Caubo, Brice Gurriet, Isabelle Petit Breuilh, Ann Inge Pastijn, N. Berreni, Michel Cosson   +13 more
semanticscholar   +1 more source

Managing vulvovaginal atrophy after breast cancer

Post Reproductive Health, 2018
Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause ...
Jenifer, Sassarini, Mahesh, Perera, Keith, Spowart, Kay, McAllister, Judith, Fraser, Ros, Glasspool, Rosie, Harrand, Marina, Chitoni, Sheila, Stallard, Mary-Ann, Lumsden   +9 more
openaire   +2 more sources

Assessing blood vascular endothelial growth factor level in patients with vulvovaginal atrophy

Obstetrics Gynecology and Reproduction
Introduction . Angiogenesis is essential for growth and development of blood vessels in normal tissues, during wound healing, and a crucial factor in tumor progression. One of the main stimulators of angiogenesis is vascular endothelial growth factor (
O. Gridasova, J. Khizroeva, A. Solopova, A. Ivanov, D. Blinov, A. Tatarintseva   +5 more
semanticscholar   +1 more source

Effects of vaginal DHEA on stress urinary incontinence in postmenopausal women with vulvovaginal atrophy.

Maturitas
OBJECTIVES To evaluate the effects of vaginal dehydroepiandrosterone (DHEA) on stress urinary incontinence (SUI) and pelvic floor muscle (PFM) function in postmenopausal women (PMW) suffering from vulvovaginal atrophy (VVA).
G. Misasi, E. Russo, M. M. Guevara, V. Tomatis, Tiziana Fidecicchi, Stefano Luisi, Andrea Giannini, Paolo Mannella, M. Caretto, Giorgio Pomara, T. Simoncini   +10 more
semanticscholar   +1 more source

Urodynamic evaluation of prasterone vaginal treatment of mild to moderate urge incontinence in women with vulvovaginal atrophy: multicenter prospective study

Menopause
Objective: This study aimed to evaluate the effects of intravaginal prasterone treatment on urge urinary symptoms in women affected by genitourinary syndrome of menopause. Methods: The study was conducted on postmenopausal women with vulvovaginal atrophy
Claudia Colla' Ruvolo, M. Ursino, Carmen Formisano, Alberto Pozzuoli, Roberta Venturella, Nicola Longo, Costantino Di Carlo   +6 more
semanticscholar   +1 more source

Changes in mucosal status, microcirculation parameters, and immunological parameters in response to combined non-hormonal therapy for vulvovaginal atrophy: A prospective study

Gynecology
Background. The relevance of age-related diseases stems from the ongoing aging of the population; in Russia, the share of women over 45 is 57.3%. The typical presentation of age-related changes includes vulvovaginal atrophy (VVA), which has extensive ...
T.M. Motovilova, L. Z. Sirotina, I.V. Martiantseva, Oksana I. Trifonova, I. A. Kruglova, K. V. Kazakova, A.D. Varnavskaya, Varvara A. Kosareva   +7 more
semanticscholar   +1 more source

Signs and symptoms of vulvovaginal atrophy (VVA) in clinical practice – the possible involvement of thyroid autoimmunity in genitourinary syndrome of menopause (GSM)

Gynecological Endocrinology
Background Thyroid autoimmune disorders (ADs) are common in midlife women and can impact various aspects of health, including sexual function. The effect of thyroid autoimmunity on the clinical manifestations of vulvovaginal atrophy (VVA) remains unclear.
L. Cucinella, F. Barbagallo, Mariacristina Erroi, C. Procaccianti, E. Martini, L. Tiranini, Giorgia E. Parrotta, Greta Monne, Giulia M. Colombo, A. Calogero, Rossella E. Nappi   +10 more
semanticscholar   +1 more source

Efficacy of vaginal mussel adhesive protein for treating postmenopausal vulvovaginal atrophy.

Age and Ageing
OBJECTIVE To compare the efficacy and safety of the vaginal mussel adhesive protein (MAP) hydrogel with the promestriene or the placebo hydrogel for treating moderate-to-severe postmenopausal vulvovaginal atrophy (VVA) symptoms.
Huan Yin, Lei Yan, Jun Zhang, Liye Shi, Chun Fu   +4 more
semanticscholar   +1 more source

Rehabilitation of patients with vulvovaginal atrophy

Journal of Medical Rehabilitation
Background. Genitourinary syndrome of menopause (GSM) is characterized by a number of pathological changes, in particular urological disorders, vulvovaginal atrophy (VVA) and sexual dysfunction. They are commonly accompanied by decreased quality of life (QoL) and often require medical intervention. At the same time, the steps taken to effectively solve
P. L. Khazan, A. N. Mnatsakanyan, D. I. Korabelnikov, D. M. Ampilogova, D. A. Petrenko   +4 more
openaire   +1 more source

Neutrophil extracellular trap biomarkers as indicators of vulvovaginal atrophy severity after cancer treatment

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Background. Vulvovaginal atrophy (VVA) following antitumor treatment is a common and clinically significant complication. At the same time, the immunoinflammatory mechanisms determining the severity and persistence of atrophic changes are yet to
A. Solopova, J. Khizroeva, O. Gridasova, V. Bitsadze, A. Ivanov, V. Galkin, A. Makatsariya   +6 more
semanticscholar   +1 more source